|
|
|
|
|
by ahoyhere
5834 days ago
|
|
Yes, exactly: if pharma is good business, and not philanthropy, then they have to focus on the people who will pay the most, the most readily, and the most often. End of story. Case in point: I'm an American who lives in Vienna, Austria, and I have recurring upper-respiratory/immune system problems. Here, I am treated with a so-cheap-it's-almost-free immune system booster called Broncho Vaxom. It's nothing but dead bacteria, but it's extremely effective (essentially an oral vaccine). It's used to save lives of children in the poorest of nations -- but it's not available in the US, because it's not profitable, whereas continuous rounds of antibiotics are. http://www.google.com/search?q=broncho%20vaxom |
|
So first responders in Florida have a problem. No coral snake antivenom.
A similar market situation applies to flu shots.
The current system favors "maintenance pharmaceuticals", not cures. Who wouldn't prefer to have a cash cow that costs the customer a few hundred dollars every month for the rest of their life, in comparison with something that actually cured them? A cure isn't very lucrative at all.
Generally, free marketeers protest that this isn't true, in the face of all evidence I can see, but look at the business logic; it's inescapable.